tldrdailynews.com logo

Wegovy: Obesity Drug Reduces Risk of Death and Heart Problems

1 min read
Source: Financial Times
TL;DR Summary

Clinical trial data shows that Novo Nordisk's obesity drug reduces the risk of death by 18%. The drug, semaglutide, was tested on over 2,000 overweight or obese adults with pre-existing cardiovascular disease or type 2 diabetes. The results indicate a significant improvement in cardiovascular outcomes and a reduction in the risk of death compared to the placebo group.

Topics:top-news#clinical-trial#health#novo-nordisk#obesity-drug#risk-of-death
Share this article
  1. Novo Nordisk's obesity drug cuts risk of death by 18%, trial data shows  Financial Times
  2. Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else?  CNN
  3. Novo Nordisk: Wegovy heart benefits due to more than weight loss  Reuters
  4. And for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetes  Medpage Today
  5. Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds  The Associated Press

Reading Insights

Total Reads

0

Unique Readers

24

Time Saved

0 min

vs 1 min read

Condensed

50%

117 → 58 words

Want the full story? Read the original article

Read on Financial Times